Suggested remit: To appraise the clinical and cost effectiveness of natalizumab within its marketing authorisation for treating highly active relapsing-remitting multiple sclerosis.
 
Status Topic selection
Technology type Medicine
Decision Not selected
Reason for decision Not eligible for Health Technology Evaluation guidance
ID number 4020

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
27 July 2022 The topic was discussed at the Topic Selection Oversight Panel (TSOP) in July 2022. Current NICE guidance already exists for natalizumab in relapsing-remitting MS (NICE TA127), yet this does not include a recommendation for highly active relapsing-remitting. Since the publication of TA127 in 2007, the subcutaneous formulation has received marketing authorisation, and it has been confirmed that natalizumab subcutaneous will continue to be commissioned across the NHS in the UK in-line with TA127. The panel concluded that conducting a separate evaluation of natalizumab for highly active relapsing-remitting multiple sclerosis would not be appropriate at this time. Should there be significant new evidence in the ‘highly active’ group, a part review of TA127 would be considered.
27 July 2022 Topic selection. Topic unselected at July 2022 TSOP as a standalone TA. Should there be significant new evidence in the ‘highly active’ group, a part review of TA127 would be considered.
18 May 2022 - 17 June 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 May 2022 In progress. Scoping commenced

For further information on how we select topics for development, please see our page about topic selection